Tardive dyskinesia (TD) and drug-induced parkinsonism are both movement disorders that are associated with dopamine receptor–blocking agents. While......READ MORE
expert roundtables by Leslie Citrome, MD, MPH; John M. Kane, MD; and Jonathan M. Meyer, MD
Patients with schizophrenia are at an inherently higher risk for cardiometabolic disease than the general population. As such, the risks of cardiom......READ MORE
expert roundtables by Leslie Citrome, MD, MPH; John M. Kane, MD; and Jonathan M. Meyer, MD
In the care of patients with schizophrenia, both medical and psychiatric comorbidities contribute to the overall clinical picture. The availability......READ MORE
patient care perspectives by Leslie Citrome, MD, MPH
Once positive symptoms are controlled, the overall goal in the maintenance phase of treatment is for the patient to develop and sustain a fulfillin......READ MORE
Patients with schizophrenia usually exhibit significant cognitive impairment. These deficits begin years before the onset of psychotic symptoms and......READ MORE
Clinicians know that treating schizophrenia effectively during the first 2 years after disease onset can have a great impact on what happens later.......READ MORE
